← Eichor
Study identifier: NCT05909709 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Dose Escalation Pilot Study to Evaluate the Safety of Alocyte for the Treatment of Facetogenic Back Pain

Condition: Facet Joints; Degeneration · Back Pain · Facet Joint Pain  ·  Sponsor: Alimorad Farshchian

PhasePhase 1
Planned participants15
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of this study is to see if the use of Alocyte (cord blood plasma plus mononucleic cells) will be safe, well tolerated, and whether it causes any side effects. The study will also examine if the use of the Investigational Product (IP) is able to reduce local inflammation or alleviate Facetogenic back pain

This description comes directly from the study's public registry record.

Talk to the study team

Ileana Simon, RN  ·  3058914686  ·  ileana@genorthix.com

Alimorad Farshchian, MD  ·  3058914686  ·  genorthix@yahoo.com

Always discuss trial participation with your own doctor first.

Locations (1)

The Center for Regenerative MedicineNorth Miami, Florida, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05909709